

CORRECTION

Open Access



Correction to: Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T

Julia Brosch-Lenz^{1*}, Carlos Uribe^{2,3}, Astrid Gosewisch¹, Lena Kaiser¹, Andrei Todica¹, Harun Ilhan¹, Franz Josef Gildehaus¹, Peter Bartenstein¹, Arman Rahmim^{2,3,4}, Anna Celler³, Sibylle Ziegler¹ and Guido Böning¹

The original article can be found online at <https://doi.org/10.1186/s40658-021-00369-4>.

* Correspondence: Julia.BroschLenz@med.uni-muenchen.de

¹Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistrasse 15, 81377 Munich, Germany

Full list of author information is available at the end of the article

Correction to: *EJNMMI Phys* 8, 26 (2021)

<https://doi.org/10.1186/s40658-021-00369-4>

Following publication of the original article [1], it was reported that due to a typesetting error some text was mistakenly introduced in the “MC method: Patient-specific Monte Carlo (MC) absorbed dose simulation” and “Comparison of dosimetry methods” sub-sections.

The erroneous text is highlighted in bold in the below passages and has been removed in the original article.

In the “MC method: Patient-specific Monte Carlo (MC) absorbed dose simulation” the affected sentence was:

A CT scan of a Gammex tissue characterization phantom (Gammex 467; Gammex Inc., Middleton, WI) using the same imaging parameters from the patient scans was **perfMC method: Patient-specificormed**, which confirmed the HU-to-density relationship of our CT device with that implemented in GATE. GATE converts HU-to-density values with internal tables based on Schneider et al. [22].

The corrected sentence reads:

A CT scan of a Gammex tissue characterization phantom (Gammex 467; Gammex Inc., Middleton, WI) using the same imaging parameters from the patient scans was performed, which confirmed the HU-to-density relationship of our CT device with that implemented in GATE. GATE converts HU-to-density values with internal tables based on Schneider et al. [22].

In the “Comparison of dosimetry methods” sub-section the affected sentence was:

The additional density **wePatient example showing the transversal slice of**figting of $VSV_{weighted}^{soft}$ and $VSV_{weighted}^{soft+bone}$, led to an overall smaller range of percentage differences than the associated method without weighting.

The corrected sentence reads:

The additional density weighting of $VSV_{weighted}^{soft}$ and $VSV_{weighted}^{soft+bone}$, led to an overall smaller range of percentage differences than the associated method without weighting.

The original article has been updated.

Author details

¹Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistrasse 15, 81377 Munich, Germany.

²PET Functional Imaging, BC Cancer, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. ³Department of Radiology, University of British Columbia, 2775 Laurel Street, Vancouver, BC V5Z 1M9, Canada. ⁴Department of Integrative Oncology, BC Cancer Research Centre, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada.

Published online: 13 April 2021

Reference

1. Brosch-Lenz J, Uribe C, Gosewisch A, et al. Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T. *EJNMMI Phys.* 2021;8:26 <https://doi.org/10.1186/s40658-021-00369-4>.